European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Thermal Evaluation of specific drug delivery with Molecularly imprinted nanoParticles developed against Estrogen Receptor

Descripción del proyecto

Un nanotransportador de fármacos simple a la vez que específico

La mortalidad asociada al cáncer de mama en los países en desarrollo en más elevada que en los países de ingresos altos. Esto pone de manifiesto el hecho de que el tratamiento no está llegando a las regiones con mayores limitaciones financieras. En este sentido, el proyecto financiado con fondos europeos TEMPER busca desarrollar nanotransportadores poliméricos de fármacos que ofrezcan una mayor eficacia y especificidad en cuanto a las dianas terapéuticas sin los efectos secundarios que se asocian habitualmente a los fármacos convencionales. Estos nanotransportadores son muy versátiles y se pueden adaptar para administrar cualquier fármaco, incluidos antibióticos contra las infecciones, o usarlos con fines de diagnóstico. La simplicidad y rentabilidad del método de administración de fármacos de TEMPER garantizará que se pueda aplicar en los países en desarrollo.

Objetivo

Breast cancer is the most commonly occurring cancer in women with over two million new cases reported in 2018. It is a genetically diverse disease with each type requiring different treatment. In developing countries, the highest amount of female cancer deaths are attributed to breast cancer with substantially lower survival rates compared to the western world. Therefore, the aim of this proposal is to develop polymeric drug nanocarriers that can improve drug efficacy, and thereby have potential to make cancer treatment available to all layers of the population including those living in deprived areas. We will develop high affinity nanoparticles that can selectively bind to certain receptors on the surface of cancer cells. When attached, the nanocarriers will release their cargo (drug compounds) specifically to the tumour and thereby improve drug efficacy and subsequently patient outcome. Furthermore, it will reduce adverse effects of common anti-cancer drugs including nausea, fatigue, hepatitis and high vulnerability to endometrial cancer. The drug delivery is usually monitored with optical techniques but the novelty of this project is to use thermal analysis, which is label-free and simple to use. The polymeric nanocarriers are highly versatile and by changing the composition, we can tailor this platform to other drug compounds or other cancer types. In addition, it has high potential as a diagnostic tool in high-throughput drug testing, customization of cellular therapy, and combating bacterial infections. This project could bring tremendous benefits in cancer treatment particularly in developing countries such as India due to its low-cost and simplicity.

Coordinador

UNIVERSITY OF NEWCASTLE UPON TYNE
Aportación neta de la UEn
€ 224 933,76
Dirección
KINGS GATE
NE1 7RU Newcastle Upon Tyne
Reino Unido

Ver en el mapa

Región
North East (England) Northumberland and Tyne and Wear Tyneside
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 224 933,76